The current market for cervical cancer diagnostics is growing at a healthy rate, which is primarily attributed to the increasing involvement of the government organizations in cervical cancer screening programs and increasing burden of the disease across the world. PAP and HPV tests are vital for diagnosis of cervical cancer. Mostly these tests are performed together for the patient age group between 21-65 years. As per the International Agency for Research on Cancer, more than 85% of cervical cancers patients are from the developing countries, which demands better efficacy screening and treatment programs for women health. Since the cancer progression is slow and may take up to 20 years to develop into an advanced stage, there are many opportunities to stop the disease before it becomes fatal. At present, there are many cities in the emerging market that lack resources for a good laboratory with highly trained cytotechnicians and other specialized staff, which is among the major challenge for good results from Pap testing. With the advancement in HPV tests, the possibility of preventing the cervical cancer has increased even in the low-resource countries (developing countries) because HPV tests are becoming more affordable. Along with that, cost-effective strategies are being implemented by the countries to leverage self-sampling.

1. INTRODUCTION

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

5. MARKET SEGMENTATION

6. COMPETITIVE LANDSCAPE

6.1 Company Profiles

6.2 Market Share Analysis (Global -Percentage and Value in USD million)

7. MARKET OPPORTUNITIES AND FUTURE TRENDS